Why Boston: The Clinical Research Anchor Behind ZMD Group's Second Region
Boston is ZMD Group's designated second region because the country's deepest concentration of academic medical centers, teaching hospitals, and translational research infrastructure is the right gravity for our integrated clinical research division. From a Boston anchor, the platform expands into other physician-rich, research-rich major metros.
Most platform-expansion decisions are answered by demographics and unit economics. Boston was answered by infrastructure. The single question we asked when we picked the second region was: where do you build a serious clinical research division if you actually intend to operate one? The answer was unambiguous.
Boston's combination of Harvard, Mass General Brigham, the Longwood Medical Area, and the surrounding biotech and translational-medicine ecosystem is the densest in the country. Anchoring the research division there gives ZMD Group the talent pool, the IRB and regulatory ecosystem, and the natural collaborator network that a credible research arm requires. Once the research anchor is in place, building a clinical and brand presence around it becomes additive rather than speculative.
Written for ZMD Group Editorial. Inquiries: [email protected].